KALARIS THERAPEUTICS INC
KLRSNASDAQTrading Snapshot
- Day Range
- $1.26 β $1.37
- 52-Week Range
- $1.33 β $11.88
- Volume (shares)
- 37,990
- Avg Volume (shares)
- β
- Shares Outstanding
- 23.8M
- Next Earnings
- 2027-03-16
Fundamentals Snapshot
- Annual Revenue
- β
- Last Q Revenue
- β
- P/E Ratio
- β
- P/S Ratio
- β
- EPS (TTM)
- $-2.09
- Dividend Yield
- β
- Dilution (1yr)
- +356.2%
KALARIS THERAPEUTICS INC
KLRSAbout KALARIS THERAPEUTICS INC
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), as well as for the treatment of other exudative and neovascular retinal diseases.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates

Kalaris Reports Third Quarter 2026 Financial Results and Provides Business Update
Preliminary data from the ongoing Phase 1b/2 study of TH103 in nAMD is now expected in 2H 2027 Recently completed technology transfer from pilot to commercial-scale manufacturer with test batches meeting target specifica

Kalaris Therapeutics Inc. (NASDAQ:KLRS) Stock Has Average Price Target of $18.75
Kalaris Therapeutics Inc. (NASDAQ: KLRS - Get Free Report) has been given an average recommendation of "Moderate Buy" by the seven brokerages that are covering the stock, Marketbeat.com reports. One research analyst has

Kalaris to Present at Morgan Stanley 24th Annual Global Healthcare Conference
BERKELEY HEIGHTS, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (βKalarisβ), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments